# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-17-008244
Filing Date
2017-08-04
Accepted
2017-08-04 16:19:39
Documents
63
Period of Report
2017-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | QUARTERLY REPORT | f10q0617_actiniumpharma.htm | 10-Q | 585016
2 | ASSIGNMENT AND CONSENT AGREEMENT, DATED JUNE 6, 2017, AMONG 275 MADISON AVENUE R | f10q0617ex10i_actinium.htm | EX-10.1 | 38480
3 | AMENDED AND RESTATED LICENSE AGREEMENT, DATED JUNE 8, 2017, BETWEEN ACTINIUM PHA | f10q0617ex10iii_actinium.htm | EX-10.3 | 28405
4 | OFFER LETTER; DATED MAY 26, 2017, BY AND BETWEEN ACTINIUM PHARMACEUTICALS, INC. | f10q0617ex10iv_actinium.htm | EX-10.4 | 75592
5 | AMENDED AND RESTATED AT-THE-MARKET MARKET ISSUANCE SALES AGREEMENT, DATED JULY 3 | f10q0617ex10v_actinium.htm | EX-10.5 | 308192
6 | AGREEMENT, DATED JUNE 6, 2017, BY AND BETWEEN ACTINIUM PHARMACEUTICALS, INC. AND | f10q0617ex10vi_actinium.htm | EX-10.6 | 19359
7 | CONSULTING AGREEMENT, DATED MAY 22, 2017, BY AND BETWEEN ACTINIUM PHARMACEUTICAL | f10q0617ex10vii_actinium.htm | EX-10.7 | 73017
8 | SEPARATION AND SETTLEMENT AGREEMENT, DATED MAY 12, 2017, BY AND BETWEEN ACTINIUM | f10q0617ex10viii_actinium.htm | EX-10.8 | 64470
9 | SEPARATION AND SETTLEMENT AGREEMENT, DATED MAY 12, 2017, BY AND BETWEEN ACTINIUM | f10q0617ex10ix_actinium.htm | EX-10.9 | 55112
10 | CERTIFICATION | f10q0617ex31i_actiniumpharm.htm | EX-31.1 | 12014
11 | CERTIFICATION | f10q0617ex31ii_actiniumpharm.htm | EX-31.2 | 12995
12 | CERTIFICATION | f10q0617ex32i_actiniumpharm.htm | EX-32.1 | 4843
13 | CERTIFICATION | f10q0617ex32ii_actiniumpharm.htm | EX-32.2 | 5937
20 | GRAPHIC | ex10iv_01.jpg | GRAPHIC | 12711
| Complete submission text file | 0001213900-17-008244.txt |  | 3915054

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
14 | XBRL DEFINITION FILE | atnm-20170630_def.xml | EX-101.DEF | 144870
15 | XBRL LABEL FILE | atnm-20170630_lab.xml | EX-101.LAB | 370976
16 | XBRL PRESENTATION FILE | atnm-20170630_pre.xml | EX-101.PRE | 241867
17 | XBRL INSTANCE FILE | atnm-20170630.xml | EX-101.INS | 493606
18 | XBRL SCHEMA FILE | atnm-20170630.xsd | EX-101.SCH | 40017
19 | XBRL CALCULATION FILE | atnm-20170630_cal.xml | EX-101.CAL | 28910

Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36374 | Film No.: 171008872
SIC: 2834 Pharmaceutical Preparations